Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease.
Amanda L ElchynskiEmily J CicaliMaria C Ferrer Del BustoAlessandra HamiltonKu-Lang ChangSiegfried O SchmidtBrian WeinerRichard DavisDavid EstoresD Max SmithKristin WiisanenJulie A JohnsonLarisa H CavallariPublished in: The pharmacogenomics journal (2021)
We aimed to determine the potential value of panel-based pharmacogenetic (PGx) testing in patients with chronic pain or gastroesophageal reflux disease (GERD) who underwent single-gene PGx testing to guide opioid or proton pump inhibitor (PPI) therapy, respectively. Of 448 patients included (chronic pain, n = 337; GERD, n = 111), mean age was 57 years, 68% were female, and 73% were white. Excluding opiates for the pain cohort and PPIs for the GERD cohort, 76.6% of patients with pain and 71.2% with GERD were prescribed at least one additional medication with a high level of PGx evidence, most commonly ondansetron or selective serotonin reuptake inhibitors. The most common genes that could inform PGx drug prescribing were CYP2C19, CYP2D6, CYP2C9, and SLCO1B1. Our findings suggest that patients with chronic pain or GERD are commonly prescribed drugs with a high level of evidence for a PGx-guided approach, supporting panel-based testing in these populations.
Keyphrases
- chronic pain
- gastroesophageal reflux disease
- pain management
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- emergency department
- stem cells
- small molecule
- drug induced
- spinal cord
- neuropathic pain
- climate change
- bone marrow
- electronic health record
- genome wide analysis
- bioinformatics analysis